GlaxoSmithKline Reports Further Progress of Oncology Portfolio

LONDON and PHILADELPHIA, May 24 /PRNewswire-USNewswire/ -- GlaxoSmithKline will present a breadth of new data at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago starting Friday, June 1st, on a wide range of innovative cancer treatments, experimental medicines and vaccines spanning more than ten prevalent cancer types.

GSK will make 30 data presentations at ASCO including 18 for TYKERB(R)/TYVERB(TM) (lapatinib), which is approved in the U.S. in combination with capecitabine (Xeloda(R)) for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab, and which was approved this week in Switzerland. GSK will also present data for other approved products and several investigational medicines, including the investigational oral angiogenesis inhibitor, pazopanib, the investigational MAGE-A3 cancer immunotherapy, and the cervical cancer candidate vaccine, CERVARIX(R), which was recently approved in Australia.

Highlights of the data to be presented at ASCO include: (For more information, please go to http://www.asco.org/)

  Breast Cancer
  -- Dr. Charles E. Geyer, Allegheny General Hospital, Pittsburgh, PA,
     Abstract #1035, Poster Discussion, Saturday, June 2, 8:00 a.m. - 1:00
     p.m., S403 and S406, Vista Room
  -- Dr. Angelo Di Leo, Hospital of Prato, Prato, Italy, Abstract #1011,
     Oral Presentation, Sunday, June 3, 11:00 a.m. - 11:15 a.m., N Hall B1
  -- Dr. Nancy U. Lin, Harvard Medical School, Boston, MA, Abstract #1012,
     Oral Presentation, Sunday, June 3, 11:15 a.m. - 11:30 a.m., N Hall B1
  -- Dr. Anna M. Storniolo, Indiana University Cancer Center, Indianapolis,
     IN, Abstract #514, Oral Presentation, Monday, June 4, 9:30 a.m. - 9:45
     a.m., E Hall D1

  Renal Cell Cancer
  -- Dr. Thomas E. Hutson, Baylor-Sammons/Texas Oncology PA, Dallas, TX,
     Abstract #5031, Poster Discussion, Saturday, June 2, 8:00 a.m. - 1:00
     p.m., S103a and S100b

  Gynecologic Cancers
  -- Dr. Michael Friedlander, Prince of Wales Hospital, Sydney, Australia,
     Abstract #5561, Poster Session, Saturday, June 2, 2:00 p.m. - 6:00
     p.m., S Hall A2
  -- Dr. Thomas W. Malpass, Virginia Mason Medical Center, Seattle, WA,
     Abstract #5570, Poster Session, Saturday, June 2, 2:00 p.m. - 6:00
     p.m., S Hall A2
  -- Dr. Jalid Sehouli, Medical Faculty of Humboldt University, Berlin,
     Germany, Abstract #5526, Poster Session, Sunday, June 3, 8:00 a.m. -
     12:00 p.m., E451a and E354a

  Soft Tissue Sarcoma
  -- Dr. Stefan Sleijfer, Erasmus University Medical Center, Rotterdam, The
     Netherlands, Abstract #10031, Poster Discussion, Monday, June 4, 2:00
     p.m. - 6:00 p.m., S103a and S404

  Non-Small Cell Lung Cancer
  -- Dr. Johan F. Vansteenkiste, University Hospital Gasthuisberg, Leuven,
     Belgium, Abstract #7554, Poster Discussion, Tuesday, June 5, 8:00 a.m.
     - 12:00 p.m., E451a and E354a

  Cervical Cancer Vaccine
  -- Dr. Tino F. Schwarz, Stiftung Juliusspital, Wuerzburg, Germany,
     Abstract #3007, Oral Presentation, Tuesday, June 5, 8:45 a.m. - 9:00
     a.m., E354a

  Non-Hodgkin's Lymphoma
  -- Dr. Christopher R. Flowers, Emory University School of Medicine,
     Atlanta, GA, Abstract #8089, Poster Session, Saturday, June 2, 8:00
     a.m. - 12:00 p.m., S Hall A2
  -- Dr. Julie Vose, University of Nebraska Medical Center, Omaha, NE,
     Abstract #8013, Oral Presentation, Sunday, June 3, 11:00 a.m. - 11:15
     a.m., E354b
  -- Dr. Mark S. Kaminski, University of Michigan Health System, Ann Arbor,
     MI Abstract #8033, Poster Discussion, Monday, June 4, 2:00 p.m. -  6:00
     p.m., E451a and E354b

  Small Cell Lung Cancer
  -- Dr. Mary E. O'Brien, Royal Marsden Hospital, Sutton, Surrey, United
     Kingdom, Abstract #7725, Poster Session, Sunday, June 3, 8:00 a.m. -
     12:00 p.m., S Hall A2

  Important Safety Information

TYKERB (lapatinib), in combination with capecitabine, is approved by the FDA for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

As with other therapies for HER2 overexpression, TYKERB has been associated with reports of decreases in left ventricular ejection fraction (LVEF). Caution should be taken if TYKERB is to be administered to patients with preexisting cardiac conditions, including uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure. LVEF should be evaluated in all patients prior to and during treatment with TYKERB.

TYKERB prolongs the QT interval in some patients. Consider ECG and electrolyte monitoring.

Diarrhea was the most common adverse event resulting in discontinuation of study medication. Proactive management of diarrhea with antidiarrheal agents is important, and severe cases of diarrhea may require administration of oral or intravenous electrolytes and fluids and interruption or discontinuation of therapy with TYKERB.

A dose reduction should be considered for patients with severe hepatic impairment.

Fetal harm can occur when administered to a pregnant woman. Women should be advised not to become pregnant when taking TYKERB.

The most common adverse events (>20%) during treatment with TYKERB plus capecitabine were diarrhea, vomiting, nausea, fatigue, palmar-plantar erythrodysesthesia, and rash.

Notes to editors:

GlaxoSmithKline (GSK) is one of the world's leading pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. Collaboration is a fundamental part of how GSK achieves its commitment to a broad spectrum of cancer care. GSK has partnered with over 160 of the leading cancer centers worldwide and is committed to these partnerships to promote breakthrough work in the field of oncology. For more information visit http://www.gsk.com/.

TYKERB(R) is a registered trademark of the GlaxoSmithKline group of companies in the United States.

TYVERB(TM) is a registered trademark of the GlaxoSmithKline group of companies in Europe.

CERVARIX(R) is a registered trademark of the GlaxoSmithKline group of companies.

  Xeloda(R) is a registered trademark of Roche Pharmaceuticals.

  Cautionary statement regarding forward-looking statements

Under the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2006.

  Enquiries:
  UK Media enquiries:            Philip Thomson       (020) 8047 5502
                                 Joss Mathieson       (020) 8047 5502
                                 Gwenan White         (020) 8047 5502

  US Media enquiries:            Nancy Pekarek        (215) 751 7709
                                 Mary Anne Rhyne      (919) 483 2839
                                 Alice Hunt           (215) 751 7709

  European Analyst/Investor      Anita Kidgell        (020) 8047 5540
  enquiries:                     Sally Ferguson       (020) 8047 5542
                                 David Mawdsley       (020) 8047 5564

  US Analyst/ Investor           Frank Murdolo        (215) 751 7002
  enquiries:                     Tom Curry            (215) 751 5419


  For on-site contact at ASCO 1-5 June 2007:
  Liad Diamond -- CERVARIX, US media only +1 215 990 5888
  Stella Gu -- CERVARIX, global media only +32 472 902 710
  Robin Fastenau -- Pazopanib and TYVERB global media +1 919 522 5237
  Sarah Alspach -- TYKERB, Hycamtin, BEXXAR US media only +1 215 287 6354
  Alice Grasset -- MAGE-A3 ASCI, +32 47 530 9020